Update on the treatment of diabetic retinopathy

TheScientificWorldJournal

Volumn 8, Issue , 2008, Pages 98-120

  Wilkinson Berka, Jennifer L ^a   Miller, Antonia G ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Advanced glycation end products; Angiotensin; Corticosteroids; Diabetic retinopathy; Growth hormone; Protein kinase C; VEGF

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADENOVIRAL PIGMENT EPITHELIAL DERIVED GROWTH FACTOR; ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; ALT 946; AMINOGUANIDINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARI 809; ATORVASTATIN; BEVACIZUMAB; CANDESARTAN; CORTICOSTEROID; FIBRIC ACID DERIVATIVE; FLUOCINOLONE ACETONIDE; GROWTH FACTOR; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; LIPID; MECAMYLAMINE; MIDOSTAURIN; PEGAPTANIB; PERINDOPRIL; PLACEBO; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

BLOOD PRESSURE REGULATION; CLINICAL STUDY; CLINICAL TRIAL; DIABETIC RETINOPATHY; DIARRHEA; DISEASE CLASSIFICATION; DRUG TARGETING; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HUMAN; INHIBITION KINETICS; INSULIN TREATMENT; LASER COAGULATION; NAUSEA; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT; VITRECTOMY; VOMITING;

ADRENAL CORTEX HORMONES; ALDEHYDE REDUCTASE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DYSLIPIDEMIAS; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN GROWTH HORMONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INSULIN; LASER COAGULATION; PROTEIN KINASE C; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN E;

EID: 39449130466     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2008.25     Document Type: Review

References (200)

1. The World Health Organization website. http://www.who.int/mediacentre/ factsheets/fs236/en/ last accessed September 2006.
2. Wilkinson, C.P., Ferris, F.L., 3rd, Klein, R.E., Lee, P.P., Agardh, C.D., Davis, M., Dills, D., Kampik, A., Pararajasegaram, R., and Verdaguer, J.T. (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110, 1677-1682.
3. Klein, R., Meuer, S.M., Moss, S.E., and Klein, B.E. (1989): The relationship of retinal microaneurysm counts to the 4-year progression of diabetic retinopathy. Arch. Ophthalmol. 107, 1780-1785.
4. Klein, R., Klein, B.E., Moss, S.E., and Cruickshanks, K.J. (1995) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102, 7-16.
5. Watkins, P.J. (2003) Retinopathy. BMJ 326, 924-926.
6. Frank, R.N. (2004) Diabetic retinopathy N. Engl. J. Med. 350, 48-58.
7. Beetham, W.P. (1963) Visual prognosis of proliferating diabetic retinopathy. Br. J. Ophthalmol. 47, 611-619.
8. Beetham, W.P., Aiello, L.M., Balodimos, M.C., and Koncz, L. (1969) Ruby-laser photocoagulation of early diabetic neovascular retinopathy: preliminary report of a long-term controlled study. Trans. Am. Ophthalmol. Soc. 67, 39-67.
9. (1978) Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 85, 82-106.
10. (1991) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98, 766-785.
11. Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 94, 761-774.
12. Lovestam-Adrian, M., Agardh, C.D., Torffvit, O., and Agardh, E. (2003) Type 1 diabetes patients with severe nonproliferative retinopathy may benefit from panretinal photocoagulation. Acta Ophthalmol. Scand. 81, 221-225.
13. La Heij, E.C., Tecim, S., Kessels, A.G., Liem, A.T., Japing, W.J., and Hendrikse, F. (2004) Clinical variables and their relation to visual outcome after vitrectomy in eyes with diabetic retinal traction detachment. Graefes Arch. Clin. Exp. Ophthalmol. 242, 210-217.
14. The Diabetic Retinopathy Vitrectomy Study Research Group (1988) Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial - Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology 95, 1307-1320.
15. Pahor, D. (1998) Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: full- versus mild-scatter coagulation. Int. Ophthalmol. 22, 313-319.
16. Aiello, L.M. (2003) Perspectives on diabetic retinopathy. Am. J. Ophthalmol. 136, 122-135.
17. Smiddy, W.E. and Flynn, H.W, Jr. (1999) Vitrectomy in the management of diabetic retinopathy. Surv. Ophthalmol. 43, 491-507.
18. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986.
19. U.K. Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853.
20. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (1993) Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22, 99-111.
21. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342, 381-389.
22. Kilpatrick, E.S., Rigby, A.S., and Atkin, S.L. (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29, 1486-1490.
23. Wang, P.H., Lau, J., and Chalmers, T.C. (1993) Meta-analysis of the effects of intensive glycemic control on late complications of type I diabetes mellitus. Online J. Curr. Clin. Trials. Doc. No. 60.
24. Egger, M., Davey Smith, G., Stettler, C., and Diem, P. (1997) Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabetes Med. 14, 919-928.
25. (1998) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch. Ophthalmol. 116, 874-886.
26. Steiner, G. (1995) Dyslipoproteinemias in diabetes. Clin. Invest. Med. 18, 282-287.
27. van Leiden, H.A., Dekker, J.M., Moll, A.C., Nijpels, G., Heine, R.J., Bouter, L.M., Stehouwer, C.D., and Polak, B.C. (2002) Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 25, 1320-1325.
28. Klein, B.E., Moss, S.E., Klein, R., and Surawicz, T.S. (1991) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98, 1261-1265.
29. Chew, E.Y., Klein, M.L., Ferris, F.L, 3rd, Remaley, N.A., Murphy, R.P., Chantry, K., Hoogwerf, B.J., and Miller, D. (1996) Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch. Ophthalmol. 114, 1079-1084.
30. Cullen, J.F., Town, S.M., and Campbell, C.J. (1974) Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans. Ophthalmol. Soc. U. K. 94, 554-562.
31. Keech, A., Simes, R.J., Barter, P., Best, J., Scott, R., Taskinen, M.R., Forder, P., Pillai, A., Davis, T., Glasziou, P., Drury, P., Kesaniemi, Y.A., Sullivan, D., Hunt, D., Colman, P., d'Emden, M., Whiting, M., Ehnholm, C., and Laakso, M. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861.
32. Athyros, V.G., Papageorgiou, A.A., Elisaf, M., and Mikhailidis, D.P. (2003) Statins and renal function in patients with diabetes mellitus. Curr. Med. Res. Opin. 19, 615-617.
33. Mooradian, AD. and Haas, M.J. (2007) Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats. Am. J. Ther. 14, 41-45.
34. Tonolo, G., Velussi, M., Brocco, E., Abaterusso, C., Carraro, A., Morgia, G., Satta, A., Faedda, R., Abhyankar, A., Luthman, H., and Nosadini, R. (2006) Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int. 70, 177-186.
35. Gotz, A.K., Boger, C.A., Hirschmann, C., Schmitz, G., Riegger, G.A., and Kramer, B.K. (2005) Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy. Eur. J. Med. Res. 10, 155-160.
36. Sen, K., Misra, A., Kumar, A., and Pandey, R.M. (2002) Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res. Clin. Pract. 56, 1-11.
37. Gordon, B., Chang, S., Kavanagh, M., Berrocal, M., Yannuzzi, L., Robertson, C., and Drexler, A. (1991) The effects of lipid lowering on diabetic retinopathy. Am. J. Ophthalmol. 112, 385-391.
38. Gupta, A., Gupta, V., Thapar, S., and Bhansali, A. (2004) Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol. 137:675-682.
39. Ozkiris, A., Erkilic, K., Koc, A., and Mistik, S. (2007) Effect of atorvastatin on ocular blood flow velocities in atients with diabetic retinopathy. Br. J. Ophthalmol. 91, 69-73.
40. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J., Thomason, M.J., Mackness, M.I., Charlton-Menys, V., and Fuller, J.H. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696.
41. Knopp, R.H., d'Emden, M., Smilde, J.G., and Pocock, S.J. (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29, 1478-1485.
42. Knowler, W.C., Bennett, P.H., and Ballintine, E.J. (1980) Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N. Engl. J. Med. 302, 645-650.
43. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317, 703-713.
44. Estacio, R.O., Jeffers, B.W., Gifford, N., and Schrier, R.W. (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2), B54-64.
45. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., Harrap, S., Poulter, N., Marre, M., Cooper, M., Glasziou, P., Grobbee, D.E., Hamet, P., Heller, S., Liu, L.S., Mancia, G., Mogensen, C.E., Pan, C.Y., Rodgers, A., and Williams, B. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840.
46. Stolk, R.P., Vingerling, J.R., Cruickshank, J.K., Hughes, A.D., Stanton, A., Juming, L., Patel, A., Thom, S.A., and Grobbee, D.E. (2007) Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp. Clin. Trials 28, 6-17.
47. Chaturvedi, N., Sjolie, A.K., Stephenson, J.M., Abrahamian, H., Keipes, M., Castellarin, A., Rogulja-Pepeonik, Z., and Fuller, J.H. (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351, 28-31.
48. Larsen, M., Hommel, E., Parving, H.H., and Lund-Andersen, H. (1990) Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 228, 505-509.
49. Sjolie, A.K. and Chaturvedi, N. (2002) The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J. Hum. Hypertens. 16(Suppl 3), S42-46.
50. Klein, R., Klein, B.E., Moss, S.E., and Wong, T.Y. (2006) The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension: Beaver Dam Eye Study. Trans. Am. Ophthalmol. Soc. 104, 98-107.
51. Wong, T.Y., Shankar, A., Klein, R., Klein, B.E., and Hubbard, L.D. (2004) Prospective cohort study of retinal vessel diameters and risk of hypertension. BMJ 329, 79.
52. Wong, T.Y., Hubbard, L.D., Klein, R., Marino, E.K., Kronmal, R., Sharrett, A.R., Siscovick, D.S., Burke, G., and Tielsch, J.M. (2002) Retinal microvascular abnormalities and blood pressure in older people: the Cardiovascular Health Study. Br. J. Ophthalmol. 86, 1007-1013.
53. Wong, T.Y., Shankar, A., Klein, R., Klein, B.E., and Hubbard, L.D. (2005) Retinal arteriolar narrowing, hypertension, and subsequent risk of diabetes mellitus. Arch. Intern. Med. 165, 1060-1065.
54. Klein, R., Klein, B.E., Moss, S.E., Wong, T.Y., Hubbard, L., Cruickshanks, K.J., and Palta, M. (2004) The relation of retinal vessel caliber to the incidence and progression of diabetic retinopathy: XIX: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch. Ophthalmol. 122, 76-83.
55. Wilkinson-Berka, J.L., Wraight, C., and Werther, G. (2006) The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr. Med. Chem. 13, 3307-3317.
56. Franken, A.A., Derkx, F.H., Schalekamp, M.A., Man in t'Veld, A.J., Hop, W.C., van Rens, E.H., and de Jong, P.T. (1988) Association of high plasma prorenin with diabetic retinopathy. J. Hypertens. Suppl. 6, S461-463.
57. Luetscher, J.A., Kraemer, F.B., Wilson, D.M., Schwartz, H.C., and Bryer-Ash, M. (1985) Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. 312, 1412-1417.
58. Danser, A.H., van den Dorpel, M.A., Deinum, J., Derkx, F.H., Franken, A.A., Peperkamp, E., de Jong, P.T., and Schalekamp, M.A. (1989) Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. 68, 160-167.
59. Berka, J.L., Stubbs, A.J., Wang, D.Z., DiNicolantonio, R., Alcorn, D., Campbell, D.J., and Skinner, S.L. (1995) Renin-containing Muller cells of the retina display endocrine features. Invest. Ophthalmol. Vis. Sci. 36, 1450-1458.
60. Danser, A.H., Derkx, F.H., Admiraal, P.J., Deinum, J., de Jong, P.T., and Schalekamp, M.A. (1994) Angiotensin levels in the eye. Invest. Ophthalmol. Vis. Sci. 35, 1008-1018.
61. Sarlos, S. and Wilkinson-Berka, J.L. (2005) The renin-angiotensin system and the developing retinal vasculature. Invest. Ophthalmol. Vis. Sci. 46, 1069-1077.
62. Ferrari-Dileo, G., Davis, E.B., and Anderson, D.R. (1991) Angiotensin II binding receptors in retinal and optic nerve head blood vessels. An autoradiographic approach. Invest. Ophthalmol. Vis. Sci. 32, 21-26.
63. Brandt, C.R., Pumfery, A.M., Micales, B., Bindley, C.D., Lyons, G.E., Sramek, S.J., and Wallow, I.H. (1994) Renin mRNA is synthesized locally in rat ocular tissues. Curr. Eye Res. 13, 755-763.
64. Wheeler-Schilling, T.H., Kohler, K., Sautter, M., and Guenther, E. (1999) Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur. J. Neurosci. 11, 3387-3394.
65. Tikellis, C., Johnston, C.I., Forbes, J.M., Burns, W.C., Thomas, M.C., Lew, R.A., Yarski, M., Smith, A.I., and Cooper, M.E. (2004) Identification of angiotensin converting enzyme 2 in the rodent retina. Curr. Eye Res. 29, 419-427.
66. Phipps, J.A., Wilkinson-Berka, J.L., and Fletcher, E.L. (2007) Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest. Ophthalmol. Vis Sci. 48, 927-934.
67. Wilkinson-Berka, J.L., Tan, G., Jaworski, K., and Ninkovic, S. (2007) Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am. J. Hypertens. 20, 423-430.
68. Gilbert, R.E., Kelly, D.J., Cox, A.J., Wilkinson-Berka, J.L., Rumble, J.R., Osicka, T., Panagiotopoulos, S., Lee, V., Hendrich, E.C., Jerums, G., and Cooper, M.E. (2000) Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43, 1360-1367.
69. Moravski, C.J., Skinner, S.L., Stubbs, A.J., Sarlos, S., Kelly, D.J., Cooper, M.E., Gilbert, R.E., and Wilkinson-Berka, J.L. (2003) The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am. J. Pathol. 162, 151-160.
70. Chen, P., Scicli, G.M., Guo, M., Fenstermacher, J.D., Dahl, D., Edwards, P.A., and Scicli, A.G. (2006) Role of angiotensin II in retinal leukostasis in the diabetic rat. Exp. Eye Res. 83, 1041-1051.
71. Bui, B.V., Armitage, J.A., Tolcos, M., Cooper, M.E., and Vingrys, A.J. (2003) ACE inhibition salvages the visual loss caused by diabetes. Diabetologia 46, 401-408.
72. Mori, F., Hikichi, T., Nagaoka, T., Takahashi, J., Kitaya, N., and Yoshida, A. (2002) Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. Br. J. Ophthalmol. 86, 1172-1174.
73. Zheng, Z., Chen, H., Xu, X., Li, C., and Gu, Q. (2007) Effects of angiotensin-converting enzyme inhibitors and betaadrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp. Eye Res. 84, 745-752.
74. Ruiz-Ortega, M., Esteban, V., and Egido, J. (2007) The regulation of the inflammatory response through nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc. Med. 17, 19-25.
75. Csukai, M. and Mochly-Rosen, D. (1999) Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Pharmacol. Res. 39, 253-259.
76. Koya, D., Haneda, M., Nakagawa, H., Isshiki, K., Sato, H., Maeda, S., Sugimoto, T., Yasuda, H., Kashiwagi, A., Ways, D.K., King, G.L., and Kikkawa, R. (2000) Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14, 439-447.
77. Kelly, D.J., Zhang, Y., Hepper, C., Gow, R.M., Jaworski, K., Kemp, B.E., Wilkinson-Berka, J.L., and Gilbert, R.E. (2003) Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52, 512-518.
78. Tuttle, K.R., Bakris, G.L., Toto, R.D., McGill, J.B., Hu, K., and Anderson, P.W. (2005) The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28, 2686-2690.
79. Kowluru, R.A., Jirousek, M.R., Stramm, L., Farid, N., Engerman, R.L., and Kern, T.S. (1998) Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes 47, 464-469.
80. Aiello, L.P., Bursell, S.E., Clermont, A., Duh, E., Ishii, H., Takagi, C., Mori, F., Ciulla, T.A., Ways, K., Jirousek, M., Smith, L.E., and King, G.L. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46, 1473-1480.
81. Nonaka, A., Kiryu, J., Tsujikawa, A, Yamashiro, K., Miyamoto, K., Nishiwaki, H., Honda, Y., and Ogura, Y. (2000) PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest. Ophthalmol. Vis. Sci. 41, 2702-2706.
82. Strom, C., Sander, B., Klemp, K., Aiello, L.P., Lund-Andersen, H., and Larsen, M. (2005) Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 46, 3855-3858.
83. PKC-DRS Study Group (2005) The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54, 2188-2197.
84. Aiello, L.P., Davis, M.D., Girach, A., Kles, K.A., Milton, R.C., Sheetz, M.J., Vignati, L., and Zhi, X.E. (2006) Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 133, 2221-2230.
85. PKC-DMES Study Group (2007) Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol. 125, 318-324.
86. Campochiaro, P.A. (2004) Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci. 45, 922-931.
87. National Institutes of Health USA. Effect of Ruboxistaurin on Clinically Significant Macula Edema.ClinicalTrials.gov identifier: NCT00133952. Last accessed 14th May 2007.
88. Wautier, J.L. and Guillausseau, P.J. (2001) Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 27, 535-542.
89. Stitt, A.W. (2001) Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br. J. Ophthalmol. 85, 746-753.
90. Brownlee, M., Vlassara, H., and Cerami, A. (1984) Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann. Intern. Med. 101, 527-537.
91. Stitt, A.W., Li, Y.M., Gardiner, T.A., Bucala, R., Archer, D.B., and Vlassara, H. (1997) Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 150, 523-531.
92. Boehm, B.O., Schilling, S., Rosinger, S., Lang, G.E., Lang, G.K., Kientsch-Engel, R., and Stahl, P. (2004) Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 47, 1376-1379.
93. Yokoi, M., Yamagishi, S.I., Takeuchi, M., Ohgami, K., Okamoto, T., Saito, W., Muramatsu, M., Imaizumi, T., and Ohno, S. (2005) Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br. J. Ophthalmol. 89, 673-675.
94. Pachydaki, S.I., Tari, S.R., Lee, S.E., Ma, W., Tseng, J.J., Sosunov, A.A., Cataldergirmen, G., Scarmeas, N., Caspersen, C., Chang, S., Schiff, W.M., Schmidt, A.M., and Barile, G.R. (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res. 82, 807-815.
95. Hughes, J.M., Kuiper, E.J., Klaassen, I., Canning, P., Stitt, A.W., Van, Bezu, J., Schalkwijk, C.G., Van, Noorden, C.J., and Schlingemann, R.O. (2007) Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia 50, 1089-1098.
96. Kaji, Y., Usui, T., Ishida, S., Yamashiro, K., Moore, T.C., Moore, J., Yamamoto, Y., Yamamoto, H., and Adamis, A.P. (2007) Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest. Ophthalmol. Vis. Sci. 48, 858-865.
97. Canning, P., Glenn, J.V., Hsu, D.K., Liu, F.T., Gardiner, T.A., and Stitt, A.W. (2007) Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp. Diabetes Res. 2007, 51837.
98. Stitt, A., Gardiner, T.A., Alderson, N.L., Canning, P., Frizzell, N., Duffy, N., Boyle, C., Januszewski, A.S., Chachich, M., Baynes, J.W., and Thorpe, S.R. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51, 2826-2832.
99. Gardiner, T.A., Anderson, H.R., and Stitt, A.W. (2003) Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J. Pathol. 201, 328-333.
100. Yamagishi, S., Amano, S., Inagaki, Y., Okamoto, T., Koga, K., Sasaki, N., Yamamoto, H., Takeuchi, M., and Makita, Z. (2002) Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun. 209, 973-978.
101. Hammes, H.P., Martin, S., Federlin, K., Geisen, K., and Brownlee, M. (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. U. S. A. 88, 11555-11558.
102. Bolton, W.K., Cattran, D.C., Williams, M.E., Adler, S.G., Appel, G.B., Cartwright, K., Foiles, P.G., Freedman, B.I., Raskin, P., Ratner, R.E., Spinowitz, B.S., Whittier, F.C., and Wuerth, J.P. (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24, 32-40.
103. Wilkinson-Berka, J.L., Kelly, D.J., Koerner, S.M., Jaworski, K., Davis, B., Thallas, V., and Cooper, M.E. (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51, 3283-3289.
104. Nakamura, S., Makita, Z., Ishikawa, S., Yasumura, K., Fujii, W., Yanagisawa, K., Kawata, T., and Koike, T. (1997) Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46, 895-899.
105. Voziyan, P.A., Khalifah, R.G., Thibaudeau, C., Yildiz, A., Jacob, J., Serianni, A.S., and Hudson, B.G. (2003) Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J. Biol. Chem. 278, 46616-46624.
106. Williams, M.E., Bolton, W.K., Khalifah, R.G., Degenhardt, T.P., Schotzinger, R.J., and McGill., J.B. (2007) Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 27, 605-614.
107. Khalifah, R.G., Chen, Y., and Wassenberg, J.J. (2005) Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann. N .Y. Acad. Sci. 1043, 793-806.
108. Figarola, J.L., Scott, S., Loera, S., Tessler. C., Chu, P., Weiss, L., Hardy, J., and Rahbar, S. (2003) LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin- diabetic rats. Diabetologia 46, 1140-1152.
109. Thallas-Bonke, V., Thorpe, S.R., Coughlan, M.T., Fukami, K., Yap, F.Y., Sourris, K., Penfold, S., Bach, L.A., Cooper. M.E., and Forbes, J.M. (2007) Inhibition of NADPH oxidase prevents AGE mediated damage in diabetic nephropathy through a protein kinase C-{alpha} dependent pathway. Diabetes Oct 24 [e-pub ahead of print]
110. Figarola, J.L., Shanmugam, N., Natarajan, R., and Rahbar, S. (2007) Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 56, 647-655.
111. Little, W.C., Zile, M.R., Kitzman, D.W., Hundley, W.G., O'Brien, T.X., and Degroof, R.C. (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J. Card. Fail. 11, 191-195.
112. Kass, D.A., Shapiro, E.P., Kawaguchi, M., Capriotti, A.R., Scuteri, A., deGroof, R.C., and Lakatta, E.G. (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104, 1464-1470.
113. Neeper, M., Schmidt, A.M., Brett, J., Yan, S.D., Wang, F., Pan, Y.C., Elliston, K., Stern, D., and Shaw, A. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267, 14998-15004.
114. Park, L., Raman, K.G., Lee, K.J., Lu, Y., Ferran, L.J., Jr., Chow, W.S., Stern, D., and Schmidt, A.M. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4, 1025-1031.
115. Malecaze, F., Clamens, S., Simorre-Pinatel, V., Mathis, A., Chollet, P., Favard, C., Bayard, F., and Plouet, J. (1994) Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. 112, 1476-1482.
116. Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., and Keshet, E. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1, 1024-1028.
117. Stone, J., Itin, A., Alon, T., Pe'er, J., Gnessin, H., Chan-Ling, T., and Keshet, E. (1995) Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 15, 4738-4747.
118. Csaky, K.G., Baffi, J.Z., Byrnes, G.A., Wolfe, J.D., Hilmer, S.C., Flippin, J., and Cousins, S.W. (2004) Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp. Eye Res. 78, 1107-1116.
119. Antonetti, D.A., Barber, A.J., Hollinger, L.A., Wolpert, E.B., and Gardner, T.W. (1999) Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 274, 23463-23467.
120. Ishida, S., Usui, T., Yamashiro, K., Kaji, Y., Ahmed, E., Carrasquillo, K.G., Amano, S., Hida, T., Oguchi, Y., and Adamis, A.P (2003) VEGF164 is proinflammatory in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 44, 2155-2162.
121. Ishida, S., Usui, T., Yamashiro, K., Kaji, Y., Amano, S., Ogura, Y., Hida, T., Oguchi, Y., Ambati, J., Miller, J.W., Gragoudas, E.S., Ng Y.S., D'Amore, P.A., Shima, D.T., and Adamis, A.P. (2003) VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198, 483-489.
122. van Eeden, P.E., Tee, L.B., Lukehurst, S., Lai, C.M., Rakoczy, E.P., Beazley, L.D., and Dunlop, S.A. (2006) Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 47, 4638-4645.
123. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611.
124. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T, Jr., Feinsod, M., and Guyer, D.R. (2004) Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816.
125. Cunningham, E.T., Jr., Adamis, A.P., Altaweel, M., Aiello, L.P., Bressler, N.M., D'Amico, D.J., Goldbaum, M., Guyer, D.R., Katz, B., Patel, M., and Schwartz, S.D. (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 122, 1747-1757.
126. Adamis, A.P., Altaweel, M., Bressler, N.M., Cunningham, E.T., Jr., Davis, M.D., Goldbaum, M., Gonzales, C., Guyer, D.R., Barrett, K., and Patel, M. (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 133, 23-28.
127. Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., and Kim, R.Y. (2006) Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431.
128. Nguyen, Q.D., Tatlipinar, S., Shah, S.M., Haller, J.A., Quinlan, E., Sung, J., Zimmer-Galler, I., Do, D.V., and Campochiaro, P.A. (2006) Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. 142, 961-969.
129. Chun, D.W., Heier, J.S., Topping, T.M., Duker, J.S., and Bankert, J.M. (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 133, 1706-1712.
130. National Institutes of Health USA. RESOLVE: Safety and Efficacy of Ranibizumb in Diabetic Macular Edema with Center Involvement. National Institutes of Health USA; ClinicalTrials.gov Identifier: NCT00284050.
131. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
132. Avery, R.L., Pieramici, D.J., Rabena, M.D., Castellarin, A.A., Nasir, M.A., and Giust, M.J. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 133, 363-372 e365.
133. Avery, R.L., Pearlman, J., Pieramici, D.J., Rabena, M.D., Castellarin, A.A., Nasir, M.A., Giust, M.J., Wendel, R., and Patel, A. (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 133, 1695.e1-15.
134. Spaide, R.F. and Fisher, Y.L. (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26, 275-278.
135. Jorge, R., Costa, R.A., Calucci, D., Cintra, L.P., and Scott, I.U. (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26, 1006-1013.
136. Wu, L., Martinez-Castellanos, M.A., Quiroz-Mercado, H., Arevalo, J.F., Berrocal, M.H., Farah, M.E., Maia, M., Roca, J.A., and Rodriguez, F.J. (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch. Clin. Exp. Ophthalmol. 246, 81-87.
137. National Eye Institute Clinical Studies Database. A phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (Avastin). http://www.nei.nih.gov/neitrials/viewStudyWeb.aspx?id=129; Last updated 17th August 2006.
138. National Institutes of Health USA. Intravitreal Bevacizumab for management of Active Progressive Proliferative Diabetic Retinopathy (PDR). ClinicalTrials.gov Identifier: nCT00370721; Last updated 6th October 2006.
139. Byrne, A.M., Bouchier-Hayes, D.J., and Harmey, J.H. (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell Mol. Med. 9, 777-794.
140. Milkiewicz, M., Ispanovic, E., Doyle, J.L., and Haas, T.L. (2006) Regulators of angiogenesis and strategies for their therapeutic manipulation. Int. J. Biochem. Cell Biol. 38, 333-357.
141. Dvorak, H.F. (2000) VPF/VEGF and the angiogenic response. Semin. Perinatol, 24, 75-78.
142. Klein, B.E., Klein, R., McBride, P.E., Cruickshanks, K.J., Palta, M., Knudtson, M.D., Moss, S.E., and Reinke, J.O. (2004) Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch. Intern. Med. 164, 1917-1924.
143. Snow, K.K. and Seddon, J.M. (1999) Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 6, 125-143.
144. Cheung, N., Rogers, S., Couper, D.J., Klein, R., Sharrett, A.R., and Wong, T.Y. (2007) Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke 38, 398-401.
145. Cheung, N., Wang, J.J., Klein, R., Couper, D.J., Sharrett, A.R., and Wong, T.Y. (2007) Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 30, 1742-1746.
146. Nishijima, K., Ng, Y.S., Zhong, L., Bradley, J., Schubert, W., Jo, N., Akita, J., Samuelsson, S.J., Robinson, G.S., Adamis, A.P., and Shima, D.T. (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53-67.
147. Kilic, U., Kilic, E., Jarve, A., Guo, Z., Spudich, A., Bieber, K., Barzena, U., Bassetti, C.L., Marti, H.H., and Hermann, D.M. (2006) Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J. Neurosci. 26, 12439-12446.
148. Kim, Y.H., Choi, M.Y., Kim, Y.S., Park, C.H., Lee, J.H., Chung, I.Y., Yoo, J.M., Choi, W.S., Cho, G.J., and Kang, S.S. (2007) Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage. Life Sci. 81, 1167-1173.
149. Kim, Y.H., Chung, I.Y., Choi, M.Y., Kim, Y.S., Lee, J.H., Park, C.H., Kang, S.S., Roh, G.S., Choi, W.S., Yoo, J.M., and Cho, G.J. (2007) Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia. Neurobiol. Dis. 26, 569-576.
150. Akkoyun, I., Yilmaz, G., Oto, S., Kahraman, B., Haberal, N., and Akova, Y.A. (2007) Impact of triamcinolone acetonide on retinal endothelial cells in a retinopathy of prematurity mouse model. Acta Ophthalmol. Scand. 85, 791-794
151. Hartnett, M.E., Martiniuk, D.J., Saito, Y., Geisen, P., Peterson, L.J., and McColm, J.R. (2006) Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci, 47, 4975-4982.
152. Brooks, H.L., Jr., Caballero, S., Jr., Newell, CK., Steinmetz, R.L., Watson, D., Segal, M.S., Harrison, J.K., Scott, E.W., and Grant, M.B. (2004) Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch. Ophthalmol. 122, 1801-1807.
153. Jonas, J.B., Kreissig, I., Spandau, U.H., and Harder, B. (2006) Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am. J. Ophthalmol. 141, 579-580.
154. Baath, J., Ells, A.L., Crichton, A., Kherani, A., and Williams, R.G. (2007) Safety profile of intravitreal triamcinolone acetonide. J. Ocul. Pharmacol. Ther. 23, 304-310.
155. Gillies, M.C., Sutter, F.K., Simpson, J.M., Larsson, J., Ali, H., and Zhu, M. (2006) Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 133, 1533-1538.
156. Westfall, A.C., Osborn, A., Kuhl, D., Benz, M.S., Mieler, W.F., and Holz, E.R. (2005) Acute endophthalmitis incidence: intravitreal triamcinolone. Arch. Ophthalmol. 123, 1075-1077.
157. Kuppermann, B.D., Blumenkranz, M.S., Haller, J.A., and Williams, G.A. (2007) An intravenous dexamethasone biodegradible drug delivery system for the treatment of persistent diabetic macular edema [e-absract 4289]. Invest. Ophthalmol. Vis Sci. http://abstracts.iovs.org.
158. National Eye Institute Clinical Studies DataBase. Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema. http://www.nei.nih.gov/neitrials/ viewStudyWeb.aspx?id=133; Last accessed 23rd March 2007.
159. Wright, A.D., McLachlan, M.S, Doyle, F.H., and Fraser, T.R. (1969) Serum growth hormone levels and size of pituitary tumour in untreated acromegaly. BMJ 4, 582-584.
160. Kohner, E.M., Joplin, G.F, Blach, R.K, Cheng, H., and Fraser, T.R. (1972) Pituitary ablation in the treatment of diabetic retinopathy. (A randomised trial). Trans. Ophthalmol. Soc. U. K. 92, 79-90.
161. Boulton, M., Gregor, Z., McLeod, D., Charteris, D., Jarvis-Evans, J., Moriarty, P., Khaliq, A., Foreman, D., Allamby, D., and Bardsley, B. (1997) Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br. J. Ophthalmol. 81, 228-233.
162. Meyer-Schwickerath, R., Pfeiffer, A., Blum, W.F., Freyberger, H., Klein, M., Losche, C., Rollmann, R., and Schatz, H. (1993) Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J. Clin. Invest. 92, 2620-2625.
163. Grant, M., Russell, B., Fitzgerald, C., and Merimee, T.J. (1986) Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes 35, 416-420.
164. Ruberte, J., Ayuso, E., Navarro, M., Carretero, A., Nacher, V., Haurigot, V., George, M., Llombart, C., Casellas, A., Costa, C., Bosch, A., and Bosch, F. (2004) Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J. Clin. Invest. 133, 1149-1157.
165. Weckbecker, G., Raulf, F., Stolz, B., and Bruns, C. (1993) Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther. 60, 245-264.
166. Thermos, K. (2003) Functional mapping of somatostatin receptors in the retina: a review. Vision Res. 43, 1805-1815.
167. Wu, P.C., Liu, C.C., Chen, C.H., Kou, H.K., Shen, S.C., Lu, C.Y., Chou, W.Y., Sung, M.T., and Yang, L.C. (2003) Inhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch. Clin. Exp. Ophthalmol. 241, 63-69.
168. Spraul, C.W., Baldysiak-Figiel, A., Lang, G.K., and Lang, G.E. (2002) Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefes Arch. Clin. Exp. Ophthalmol. 240, 227-231.
169. Bezerra, Y., Fuselier, J.A., Peyman, G.A., Oner, H., Drouant, G., and Coy, D.H. (2005) Study of inhibitory effects of an antiangiogenic somatostatin-camptothecin conjugate on laser-induced choroidal neovascularization in rats. Retina 25, 345-354.
170. Kirkegaard, C., Norgaard, K., Snorgaard, O., Bek, T., Larsen, M., and Lund-Andersen, H. (1990) Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol. (Copenh.) 122, 766-772.
171. Grant, M.B., Mames, R.N., Fitzgerald, C., Hazariwala, K.M., Cooper-DeHoff, R., Caballero, S., and Estes, K.S. (2000) The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23, 504-509.
172. National Institutes of Health USA. Extension Study of the Long-Term Safety and Tolerability of Octreotide Acetate in Patients with Moderately Severe of Severe Non-Proliferative Diabetic Retinopathy or Low Risk Diabetic Retinopathy. NCT00248157; ClinicalTrials.gov Identifier: NCT00248131.
173. National Institutes of Health USA. Extension Study of the Long-Term Safety and Tolerability of Octreotide Acetate in Patients with Moderately Severe or Severe Non-Proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy. ClinicalTrials.gov Identifier: NCT00248157; Last accessed 6th August 2007.
174. Grant, M. (2006) Diabetic Retinopathy - Diagnostic and Treatment Novelties. Presented at the American Association 66th Scientific Sessions.
175. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group (2001) The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108, 2266-2272.
176. Smith, L.E., Kopchick, J.J., Chen, W., Knapp, J., Kinose, F., Daley, D., Foley, E., Smith, R.G., and Schaeffer, J.M. (1997) Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276, 1706-1709.
177. Wilkinson-Berka, J.L., Lofthouse, S., Jaworski, K., Ninkovic, S., Tachas, G., and Wraight, C. (2007) An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularization in a mouse model of retinopathy. Mol. Vis. 13:1529-1538.
178. Gabbay, K.H. (175) Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu. Rev. Med. 26, 521-536.
179. Cheung, A.K., Fung, M.K., Lo. A.C., Lam, T.T., So, K.F., Chung, S.S., and Chung, S.K. (2005) Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 54, 3119-3125.
180. Kato, N., Yashima, S., Suzuki, T., Nakayama, Y., and Jomori, T. (2003) Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J. Diabetes Complications 17, 374-379.
181. Cusick, M., Chew, E.Y., Ferris, F., 3rd, Cox, T.A., Chan, C.C., and Kador, P.F. (2003) Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Arch. Ophthalmol. 121, 1745-1751.
182. Obrosova, I.G., Minchenko, A.G., Vasupuram, R., White, L., Abatan, O.I., Kumagai, A.K., Frank R.N., and Stevens, M.J. (2003) Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52, 864-871.
183. Asnaghi, V., Gerhardinger, C., Hoehn, T., Adeboje, A., and Lorenzi, M. (2003) A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 52, 506-511.
184. Sorbinil Retinopathy Trial Research Group (1990) A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch. Ophthalmol. 108, 1234-1244.
185. Oates, P.J. and Mylari, B.L. (199) Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin. Investig. Drugs 8, 2095-2119.
186. Sun, W., Oates, P.J., Coutcher, J.B., Gerhardinger, C., and Lorenzi, M. (2006) A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 55, 2757-2762.
187. Kunisaki, M., Bursell, S.E., Clermont, A.C., Ishii, H., Ballas, L.M., Jirousek, M.R., Umeda, F., Nawata, H., and King, G.L. (1995) Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am. J. Physiol. 269, E239-246.
188. Bursell, S.E., Clermont, A.C., Aiello, L.P., Aiello, L.M., Schlossman, D.K., Feener, E.P., Laffel, L., and King, G.L. (1999) High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 22, 1245-1251.
189. Dorrell, M., Uusitalo-Jarvinen, H., Aguilar, E., and Friedlander, M. (2007) Ocular neovascularization: basic mechanisms and therapeutic advances. Surv. Ophthalmol. 52(Suppl. 1), S3-19.
190. Zhang, S.X., Wang, J.J., Gao, G., Parke, K., and Ma, J.X. (2006) Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J. Mol. Endocrinol. 37, 1-12.
191. Stellmach, V., Crawford, S.E., Zhou, W., and Bouck, N. (2001) Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. U. S. A. 98, 2593-2597.
192. Zhang, S.X., Wang, J.J., Gao, G., Shao, C., Mott, R., and Ma, J.X. (2006) Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 20, 323-325.
193. Rasmussen, H., Chu, K.W., Campochiaro, P., Gehlbach, P.L., Haller, J.A., Handa, J.T., Nguyen, Q.D., and Sung, J.U. (2001) Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum. Gene Ther. 12, 2029-2032.
194. Saishin, Y., Saishin, Y., Takahashi, K., Lima e Silva, R., Hylton, D., Rudge, J.S., Wiegand, S.J., and Campochiaro, P.A. (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell Physiol. 195, 241-248.
195. Qaum, T., Xu, Q., Joussen, A.M., Clemens, M.W., Qin, W., Miyamoto, K., Hassessian, H., Wiegand, S.J., Rudge, J., Yancopoulos, G.D., and Adamis, A.P. (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42, 2408-2413.
196. Nguyen, Q.D., Shah, S.M., Hafiz, G., Quinlan, E., Sung, J., Chu, K., Cedarbaum, J.M., and Campochiaro, P.A. (2006) A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113, 1522.e1-1522.e14.
197. Shen, J., Samul, R., Silva, R.L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S.F., Zinnen, S., Kossen, K., Fosnaugh, K., Vargeese, C., Gomez, A., Bouhana, K., Aitchison, R., Pavco, P., and Campochiaro, P.A. (2006) Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 13, 225-234.
198. Segal, M.S., Shah, R., Afzal, A., Perrault, C.M., Chang, K., Schuler, A., Beem, E., Shaw, L.C., Li Calzi, S., Harrison, J.K., Tran-Son-Tay, R., and Grant, M.B. (2006) Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 55, 102-109.
199. Caballero, S., Sengupta, N., Afzal, A., Chang, K.H., Li, Calzi, S., Guberski, D.L., Kern, T.S., and Grant, M.B. (2007) Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 56, 960-967.
200. Chang, K.H., Chan-Ling, T., McFarland, E.L., Afzal, A., Pan, H., Baxter, L.C., Shaw, L.C., Caballero, S., Sengupta, N., Li, Calzi, S., Sullivan, S.M., and Grant, M.B. (2007) IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc. Natl. Acad. Sci. U. S. A. 104, 10595-10600.